The NM_000329.3(RPE65):c.95-2A>T variant disrupts a canonical splice site in intron 2 and is predicted to lead to skipping of a critical exon in which missense variants have previously been established as a mechanism of disease (PVS1). At least 6 probands have been reported with this variant, one of whom displayed markedly impaired night vision (0.5 pts), reduced visual acuity 20/60 from an early age (1 pt), nystagmus (1 pt), RPE demelanization (0.5 pts), poor pupillary light response (0.5 pts), significant outer nuclear layer preservation for the severity of visual loss (1 pt), nondetectable ERG responses from rods (0.5 pts) and cones (1 pt), and minimal autofluorescence (2 pts), which together are highly specific for RPE65 retinopathy (8 pts total, PP4_Moderate, PMID: 20604683). The proband's affected sibling II:2 is also homozygous for this variant (PP1). At least 3 probands with the required phenotype of extinguished ERG harbor the variant in the homozygous state (1 point, PMID: 20604683, PMID: 17724218, PMID: 15024725, PM3). This variant is present in gnomAD v.2.1.1 at a GrpMax allele frequency of 0.00002298, with 3 alleles / 34592 total alleles in the Admixed American population, which is lower than the ClinGen LCA / eoRD VCEP PM2_Supporting threshold of <0.0002 (PM2_Supporting). In summary, this variant meets the criteria to be classified as Pathogenic for RPE65-related recessive retinopathy based on the ACMG/AMP criteria applied, as specified by the ClinGen LCA/eoRD VCEP: PVS1, PP4_Moderate, PM2_Supporting, PM3, and PP1. (VCEP specifications version 1.0.0; date of approval 09/21/2023).